CL2013000733A1 - Compuestos derivados de arilalquilimidazol, moduladores selectivos de receptores alfa 2 adrenergicos; y composicion farmaceutica que los comprende. - Google Patents

Compuestos derivados de arilalquilimidazol, moduladores selectivos de receptores alfa 2 adrenergicos; y composicion farmaceutica que los comprende.

Info

Publication number: CL2013000733A1
Authority: CL; Chile
Prior art keywords: arylalkylimidazole; alpha; pharmaceutical composition; compounds derived; adrenergic receptors
Prior art date: 2010-09-16

Application number

CL2013000733A

Other languages

English (en)

Inventor

Mohammed I Dibas

Daniel W Gil

Ken Chow

Liming Wang

Michael E Garst

John E Donello

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-16

Filing date

2013-03-18

Publication date

2013-08-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000733(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-18 Application filed by Allergan Inc filed Critical Allergan Inc

2013-08-23 Publication of CL2013000733A1 publication Critical patent/CL2013000733A1/es

Links

102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 title 1
108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

CL2013000733A 2010-09-16 2013-03-18 Compuestos derivados de arilalquilimidazol, moduladores selectivos de receptores alfa 2 adrenergicos; y composicion farmaceutica que los comprende. CL2013000733A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US38337010P	2010-09-16	2010-09-16

Publications (1)

Publication Number	Publication Date
CL2013000733A1 true CL2013000733A1 (es)	2013-08-23

Family

ID=44675870

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
CL2013000735A CL2013000735A1 (es)	2010-09-16	2013-03-18	Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
CL2013000734A CL2013000734A1 (es)	2010-09-16	2013-03-18	Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico.
CL2013000736A CL2013000736A1 (es)	2010-09-16	2013-03-18	Uso de prodrogas ester de [3-(1-(1h-imidazol-4-il)etil)-2-metil-fenil]metanol para preparar un medicamento util en el tratamiento de enfermedades de la retina tales como degeneracion macular humeda y seca, y retinopatia diabetica; y uso de la composicion que comprende a dichos compuestos.
CL2013000733A CL2013000733A1 (es)	2010-09-16	2013-03-18	Compuestos derivados de arilalquilimidazol, moduladores selectivos de receptores alfa 2 adrenergicos; y composicion farmaceutica que los comprende.

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
CL2013000735A CL2013000735A1 (es)	2010-09-16	2013-03-18	Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
CL2013000734A CL2013000734A1 (es)	2010-09-16	2013-03-18	Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico.
CL2013000736A CL2013000736A1 (es)	2010-09-16	2013-03-18	Uso de prodrogas ester de [3-(1-(1h-imidazol-4-il)etil)-2-metil-fenil]metanol para preparar un medicamento util en el tratamiento de enfermedades de la retina tales como degeneracion macular humeda y seca, y retinopatia diabetica; y uso de la composicion que comprende a dichos compuestos.

Country Status (28)

Country	Link
US (9)	US8501796B2 (es)
EP (13)	EP3053576B1 (es)
JP (4)	JP6073229B2 (es)
KR (7)	KR20140005154A (es)
CN (5)	CN105412092B (es)
AR (4)	AR083020A1 (es)
AU (4)	AU2011301856C1 (es)
BR (4)	BR112013006355A2 (es)
CA (8)	CA3116249A1 (es)
CL (4)	CL2013000735A1 (es)
CY (3)	CY1121024T1 (es)
DK (9)	DK3636263T3 (es)
ES (10)	ES2607084T3 (es)
HU (5)	HUE049573T2 (es)
IL (4)	IL225282A0 (es)
MX (4)	MX2013003009A (es)
MY (4)	MY161607A (es)
NZ (1)	NZ608751A (es)
PL (7)	PL3050563T3 (es)
PT (7)	PT3338777T (es)
RU (4)	RU2013116405A (es)
SG (4)	SG188572A1 (es)
SI (5)	SI3050563T1 (es)
TR (1)	TR201909249T4 (es)
TW (4)	TW201305116A (es)
UA (1)	UA112973C2 (es)
WO (4)	WO2012037484A1 (es)
ZA (4)	ZA201302194B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2395999B1 (en) *	2009-02-13	2017-09-13	Allergan, Inc.	Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
CN102724878A (zh)	2010-01-11	2012-10-10	奥雷西根治疗公司	在重度抑郁症患者中提供体重减轻疗法的方法
US8501796B2 (en) *	2010-09-16	2013-08-06	Allergan, Inc.	Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
MX2014000871A (es) *	2011-07-22	2014-06-23	Allergan Inc	Moduladores adrenergicos alfa-2 para el tratamiento de trastornos visuales mediados por proyecciones visuales centrales desde el ojo.
WO2013078151A1 (en)	2011-11-21	2013-05-30	Allergan, Inc.	Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
USD794650S1 (en)	2014-11-28	2017-08-15	Samsung Electronics Co., Ltd.	Display screen or portion thereof with a graphical user interface
CN108310442B (zh) *	2017-01-17	2021-08-27	台北科技大学	眼科用组合物
KR102050506B1 (ko)	2017-06-20	2019-11-29	한국식품연구원	망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) *	2018-07-09	2021-03-23	成都倍特药业股份有限公司	一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
CN112552314B (zh) *	2018-08-24	2022-03-04	杭州阿诺生物医药科技有限公司	Sting激动剂小分子抗肿瘤化合物及其应用
BR112023021140A2 (pt) *	2021-04-16	2023-12-12	Ads Therapeutics Llc	Cofármaco compreendendo uma fração de agonista muscarínico e uma fração de agonista alfa2 adrenérgico, ou um sal farmacêutico deste, composição farmacêutica e formulação farmacêutica
KR20250141793A (ko) *	2023-02-08	2025-09-29	보슈 롬 아일랜드 리미티드	시력을 개선시키기 위한 알파-2-아드레날린성 효능제
WO2025179071A1 (en) *	2024-02-20	2025-08-28	Bausch + Lomb Ireland Limited	Sustained-release drug delivery compositions for treating ocular diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG45449A1 (en)	1992-05-13	1998-01-16	Sandoz Ltd	Ophthalmic compositions
US5459133A (en) *	1992-06-05	1995-10-17	Telor Ophthalmic Pharmaceuticals, Inc.	Methods and products for treating presbyopia
NZ276883A (en)	1993-11-15	1998-08-26	Schering Corp	1h-imidazol-4-yl)alkyl]benzene derivatives
US5474979A (en)	1994-05-17	1995-12-12	Allergan, Inc.	Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) *	1998-05-12	1999-11-17	Schwarz Pharma Ag	Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) *	2000-07-14	2004-10-28	Allergan, Inc.	Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en)	2001-05-03	2002-12-26	Allergan Sales Inc.	Compositions having enhanced pharmacokinetic characteristics
US7439241B2 (en) *	2003-05-27	2008-10-21	Galderma Laboratories, Inc.	Compounds, formulations, and methods for treating or preventing rosacea
WO2004106307A2 (fr) *	2003-05-27	2004-12-09	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)	Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament
EP1658717A1 (en) *	2003-07-14	2006-05-24	Koninklijke Philips Electronics N.V.	Projection device
MXPA06002716A (es)	2003-09-12	2006-06-06	Allergan Inc	Metodos y composiciones para el tratamiento de dolor y otras condiciones mediadas por adrenergicos de alfa-2.
US20050059583A1 (en)	2003-09-15	2005-03-17	Allergan, Inc.	Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) *	2004-04-30	2005-11-03	Allergan, Inc.	Sustained release intraocular implants and methods for treating ocular vasculopathies
CN101426502A (zh)	2004-05-25	2009-05-06	桑斯罗萨医药发展公司	治疗或预防炎症性皮肤疾病的化合物、制剂及方法
US20050277584A1 (en)	2004-06-09	2005-12-15	Allergan, Inc.	Pharmaceutical compositions comprising cyclosporins
WO2006036480A1 (en) *	2004-09-24	2006-04-06	Allergan, Inc.	4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
US7931909B2 (en)	2005-05-10	2011-04-26	Allergan, Inc.	Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20070015691A1 (en)	2005-07-13	2007-01-18	Allergan, Inc.	Cyclosporin compositions
US7297679B2 (en)	2005-07-13	2007-11-20	Allergan, Inc.	Cyclosporin compositions
US20070082070A1 (en) *	2005-10-11	2007-04-12	Stookey Evangeline L	Treating skin disorders
US7902247B2 (en)	2008-01-09	2011-03-08	Allergan, Inc.	Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
CA2751651A1 (en)	2009-02-06	2010-08-12	Allergan, Inc.	Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
EP2395999B1 (en) *	2009-02-13	2017-09-13	Allergan, Inc.	Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US8394800B2 (en) *	2009-11-19	2013-03-12	Galderma Laboratories, L.P.	Method for treating psoriasis
US8501796B2 (en) *	2010-09-16	2013-08-06	Allergan, Inc.	Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure

2011
- 2011-09-15 US US13/233,844 patent/US8501796B2/en active Active
- 2011-09-15 US US13/233,891 patent/US8492557B2/en active Active
- 2011-09-15 US US13/233,665 patent/US8492422B2/en active Active
- 2011-09-15 US US13/233,382 patent/US8653123B2/en active Active
- 2011-09-16 DK DK19194325.7T patent/DK3636263T3/da active
- 2011-09-16 MY MYPI2013000932A patent/MY161607A/en unknown
- 2011-09-16 PT PT181571472T patent/PT3338777T/pt unknown
- 2011-09-16 DK DK16161922.6T patent/DK3053576T3/en active
- 2011-09-16 PT PT117609628T patent/PT2616068T/pt unknown
- 2011-09-16 ES ES11760962.8T patent/ES2607084T3/es active Active
- 2011-09-16 TW TW100133487A patent/TW201305116A/zh unknown
- 2011-09-16 SI SI201131547T patent/SI3050563T1/sl unknown
- 2011-09-16 TW TW100133488A patent/TW201240661A/zh unknown
- 2011-09-16 PT PT117609636T patent/PT2616069T/pt unknown
- 2011-09-16 CA CA3116249A patent/CA3116249A1/en active Pending
- 2011-09-16 CA CA3077732A patent/CA3077732A1/en active Pending
- 2011-09-16 JP JP2013529373A patent/JP6073229B2/ja active Active
- 2011-09-16 KR KR1020137009505A patent/KR20140005154A/ko not_active Withdrawn
- 2011-09-16 ES ES18157147T patent/ES2788051T3/es active Active
- 2011-09-16 RU RU2013116405/15A patent/RU2013116405A/ru unknown
- 2011-09-16 CA CA3122745A patent/CA3122745A1/en active Pending
- 2011-09-16 RU RU2013116763/15A patent/RU2013116763A/ru not_active Application Discontinuation
- 2011-09-16 EP EP16161922.6A patent/EP3053576B1/en active Active
- 2011-09-16 UA UAA201304644A patent/UA112973C2/uk unknown
- 2011-09-16 AU AU2011301856A patent/AU2011301856C1/en active Active
- 2011-09-16 WO PCT/US2011/051979 patent/WO2012037484A1/en not_active Ceased
- 2011-09-16 TR TR2019/09249T patent/TR201909249T4/tr unknown
- 2011-09-16 EP EP16161923.4A patent/EP3050564B1/en active Active
- 2011-09-16 MY MYPI2013000930A patent/MY191369A/en unknown
- 2011-09-16 ES ES11760963.6T patent/ES2613509T3/es active Active
- 2011-09-16 MY MYPI2013000907A patent/MY173846A/en unknown
- 2011-09-16 SG SG2013019575A patent/SG188572A1/en unknown
- 2011-09-16 PL PL16161920T patent/PL3050563T3/pl unknown
- 2011-09-16 AU AU2011301847A patent/AU2011301847B2/en active Active
- 2011-09-16 AR ARP110103392A patent/AR083020A1/es unknown
- 2011-09-16 DK DK16161920.0T patent/DK3050563T3/en active
- 2011-09-16 MX MX2013003009A patent/MX2013003009A/es active IP Right Grant
- 2011-09-16 BR BR112013006355A patent/BR112013006355A2/pt not_active IP Right Cessation
- 2011-09-16 PT PT181601741T patent/PT3348264T/pt unknown
- 2011-09-16 BR BR112013006320-3A patent/BR112013006320B1/pt active IP Right Grant
- 2011-09-16 MX MX2013003008A patent/MX2013003008A/es active IP Right Grant
- 2011-09-16 PL PL11760963T patent/PL2616069T3/pl unknown
- 2011-09-16 ES ES16161922.6T patent/ES2684055T3/es active Active
- 2011-09-16 ES ES19194325T patent/ES2904479T3/es active Active
- 2011-09-16 EP EP19217499.3A patent/EP3698789A1/en not_active Withdrawn
- 2011-09-16 AR ARP110103389A patent/AR083017A1/es not_active Application Discontinuation
- 2011-09-16 KR KR1020137009502A patent/KR101840500B1/ko active Active
- 2011-09-16 PT PT16161922T patent/PT3053576T/pt unknown
- 2011-09-16 DK DK16161921.8T patent/DK3078376T3/da active
- 2011-09-16 PL PL18160174T patent/PL3348264T3/pl unknown
- 2011-09-16 SG SG2013019591A patent/SG188573A1/en unknown
- 2011-09-16 SI SI201131550T patent/SI3053576T1/sl unknown
- 2011-09-16 HU HUE18160174A patent/HUE049573T2/hu unknown
- 2011-09-16 EP EP11760962.8A patent/EP2616068B1/en active Active
- 2011-09-16 AU AU2011301901A patent/AU2011301901B2/en active Active
- 2011-09-16 CA CA2812195A patent/CA2812195A1/en not_active Abandoned
- 2011-09-16 EP EP18157147.2A patent/EP3338777B1/en active Active
- 2011-09-16 SI SI201131819T patent/SI3050564T1/sl unknown
- 2011-09-16 KR KR1020197004880A patent/KR102104760B1/ko active Active
- 2011-09-16 WO PCT/US2011/051926 patent/WO2012037453A1/en not_active Ceased
- 2011-09-16 MY MYPI2013000931A patent/MY168763A/en unknown
- 2011-09-16 AR ARP110103391A patent/AR083019A1/es unknown
- 2011-09-16 ES ES16161923T patent/ES2760920T3/es active Active
- 2011-09-16 ES ES16161921T patent/ES2737230T3/es active Active
- 2011-09-16 DK DK18157147.2T patent/DK3338777T3/da active
- 2011-09-16 HU HUE16161923A patent/HUE047476T2/hu unknown
- 2011-09-16 AR ARP110103390A patent/AR083018A1/es unknown
- 2011-09-16 PL PL16161923T patent/PL3050564T3/pl unknown
- 2011-09-16 TW TW100133491A patent/TWI591058B/zh active
- 2011-09-16 EP EP18160174.1A patent/EP3348264B1/en active Active
- 2011-09-16 ES ES18160174T patent/ES2781681T3/es active Active
- 2011-09-16 HU HUE16161920A patent/HUE038698T2/hu unknown
- 2011-09-16 HU HUE16161922A patent/HUE039090T2/hu unknown
- 2011-09-16 CA CA2812191A patent/CA2812191C/en active Active
- 2011-09-16 CN CN201510767798.7A patent/CN105412092B/zh active Active
- 2011-09-16 CN CN2011800545690A patent/CN103221045A/zh active Pending
- 2011-09-16 PT PT161619234T patent/PT3050564T/pt unknown
- 2011-09-16 ES ES16161920.0T patent/ES2687420T3/es active Active
- 2011-09-16 RU RU2013116541A patent/RU2612351C2/ru active
- 2011-09-16 CA CA2811559A patent/CA2811559A1/en active Pending
- 2011-09-16 PL PL16161922T patent/PL3053576T3/pl unknown
- 2011-09-16 EP EP11760963.6A patent/EP2616069B1/en active Active
- 2011-09-16 NZ NZ60875111A patent/NZ608751A/en unknown
- 2011-09-16 CN CN2011800546049A patent/CN103209694A/zh active Pending
- 2011-09-16 EP EP11760961.0A patent/EP2616067B1/en active Active
- 2011-09-16 KR KR1020137009506A patent/KR101952457B1/ko active Active
- 2011-09-16 BR BR112013006362A patent/BR112013006362A2/pt not_active IP Right Cessation
- 2011-09-16 HU HUE18157147A patent/HUE048725T2/hu unknown
- 2011-09-16 KR KR1020137009503A patent/KR101840501B1/ko active Active
- 2011-09-16 EP EP11760958.6A patent/EP2616066B1/en active Active
- 2011-09-16 CA CA3079450A patent/CA3079450A1/en active Pending
- 2011-09-16 MX MX2013003002A patent/MX2013003002A/es active IP Right Grant
- 2011-09-16 AU AU2011301932A patent/AU2011301932C1/en active Active
- 2011-09-16 DK DK18160174.1T patent/DK3348264T3/da active
- 2011-09-16 EP EP20153104.3A patent/EP3659600A1/en not_active Withdrawn
- 2011-09-16 JP JP2013529372A patent/JP6045495B2/ja active Active
- 2011-09-16 RU RU2013116403/15A patent/RU2013116403A/ru not_active Application Discontinuation
- 2011-09-16 SI SI201131868T patent/SI3338777T1/sl unknown
- 2011-09-16 CA CA2812197A patent/CA2812197C/en active Active
- 2011-09-16 ES ES11760958.6T patent/ES2593612T3/es active Active
- 2011-09-16 KR KR1020207011231A patent/KR102139905B1/ko active Active
- 2011-09-16 CN CN201180053895XA patent/CN103200942A/zh active Pending
- 2011-09-16 EP EP19194325.7A patent/EP3636263B1/en active Active
- 2011-09-16 DK DK11760962.8T patent/DK2616068T3/en active
- 2011-09-16 SG SG2013019567A patent/SG188571A1/en unknown
- 2011-09-16 SG SG2013019559A patent/SG188570A1/en unknown
- 2011-09-16 EP EP16161921.8A patent/EP3078376B1/en active Active
- 2011-09-16 PL PL11760962.8T patent/PL2616068T3/pl unknown
- 2011-09-16 DK DK16161923T patent/DK3050564T3/da active
- 2011-09-16 DK DK11760963.6T patent/DK2616069T3/en active
- 2011-09-16 CN CN201180053886.0A patent/CN103200941B/zh active Active
- 2011-09-16 PL PL18157147T patent/PL3338777T3/pl unknown
- 2011-09-16 JP JP2013529371A patent/JP2013537236A/ja not_active Withdrawn
- 2011-09-16 EP EP16161920.0A patent/EP3050563B1/en active Active
- 2011-09-16 BR BR112013006352A patent/BR112013006352A2/pt not_active IP Right Cessation
- 2011-09-16 MX MX2013003004A patent/MX2013003004A/es active IP Right Grant
- 2011-09-16 PT PT16161920T patent/PT3050563T/pt unknown
- 2011-09-16 JP JP2013529360A patent/JP2013541527A/ja not_active Withdrawn
- 2011-09-16 WO PCT/US2011/051990 patent/WO2012037490A1/en not_active Ceased
- 2011-09-16 WO PCT/US2011/052004 patent/WO2012037499A1/en not_active Ceased
- 2011-09-16 SI SI201131857T patent/SI3348264T1/sl unknown
- 2011-09-16 KR KR1020207021626A patent/KR102354097B1/ko active Active
- 2011-09-16 TW TW100133498A patent/TW201240662A/zh unknown
2013
- 2013-03-17 IL IL225282A patent/IL225282A0/en unknown
- 2013-03-17 IL IL225280A patent/IL225280A0/en active IP Right Grant
- 2013-03-17 IL IL225281A patent/IL225281A0/en unknown
- 2013-03-17 IL IL225278A patent/IL225278A/en active IP Right Grant
- 2013-03-18 CL CL2013000735A patent/CL2013000735A1/es unknown
- 2013-03-18 CL CL2013000734A patent/CL2013000734A1/es unknown
- 2013-03-18 CL CL2013000736A patent/CL2013000736A1/es unknown
- 2013-03-18 CL CL2013000733A patent/CL2013000733A1/es unknown
- 2013-03-25 ZA ZA2013/02194A patent/ZA201302194B/en unknown
- 2013-03-25 ZA ZA2013/02193A patent/ZA201302193B/en unknown
- 2013-03-27 ZA ZA2013/02291A patent/ZA201302291B/en unknown
- 2013-03-27 ZA ZA2013/02288A patent/ZA201302288B/en unknown
- 2013-06-13 US US13/916,888 patent/US20130289088A1/en not_active Abandoned
- 2013-06-24 US US13/925,502 patent/US20130296394A1/en not_active Abandoned
- 2013-11-04 US US14/071,090 patent/US8853251B2/en active Active
2015
- 2015-01-29 US US14/608,458 patent/US20150148394A1/en not_active Abandoned
2016
- 2016-08-18 US US15/240,219 patent/US20160354346A1/en not_active Abandoned
2018
- 2018-08-13 CY CY181100852T patent/CY1121024T1/el unknown
2020
- 2020-03-20 CY CY20201100265T patent/CY1122958T1/el unknown
- 2020-04-21 CY CY20201100365T patent/CY1122809T1/el unknown

Also Published As

Publication number	Publication date
TW201240662A (en)	2012-10-16
CA2812195A1 (en)	2012-03-22
PT2616068T (pt)	2016-09-13
AR083018A1 (es)	2013-01-23
JP2013540749A (ja)	2013-11-07
RU2013116403A (ru)	2014-10-27
AU2011301901B2 (en)	2016-02-11
US20120142746A1 (en)	2012-06-07
ES2904479T3 (es)	2022-04-05
EP3050563B1 (en)	2018-05-09
KR20130105658A (ko)	2013-09-25
RU2013116763A (ru)	2014-10-27
KR101840501B1 (ko)	2018-05-04
HUE038698T2 (hu)	2018-11-28
EP2616067A1 (en)	2013-07-24
AU2011301847A1 (en)	2013-05-02
AU2011301932B2 (en)	2016-02-25
IL225278A0 (en)	2013-06-27
US8501796B2 (en)	2013-08-06
EP3348264A1 (en)	2018-07-18
PL3050564T3 (pl)	2020-06-01
BR112013006355A2 (pt)	2016-06-28
ES2607084T3 (es)	2017-03-29
CA2812191A1 (en)	2012-03-22
PL3050563T3 (pl)	2018-12-31
CN103221045A (zh)	2013-07-24
EP2616069B1 (en)	2016-11-16
WO2012037499A1 (en)	2012-03-22
CA3079450A1 (en)	2012-03-22
WO2012037484A1 (en)	2012-03-22
SI3348264T1 (sl)	2020-07-31
PL2616068T3 (pl)	2016-11-30
PT3050564T (pt)	2019-12-11
WO2012037490A1 (en)	2012-03-22
EP3053576A1 (en)	2016-08-10
CA2812191C (en)	2021-04-13
EP3659600A1 (en)	2020-06-03
DK3078376T3 (da)	2019-06-24
HUE039090T2 (hu)	2018-12-28
ES2788051T3 (es)	2020-10-20
CN105412092B (zh)	2020-11-17
ES2760920T3 (es)	2020-05-18
TW201240661A (en)	2012-10-16
MX2013003004A (es)	2013-06-28
PL3338777T3 (pl)	2020-07-13
HK1185539A1 (zh)	2014-02-21
ES2593612T3 (es)	2016-12-12
CN103209694A (zh)	2013-07-17
US20160354346A1 (en)	2016-12-08
DK2616069T3 (en)	2016-12-19
ES2684055T3 (es)	2018-10-01
CA2812197A1 (en)	2012-03-22
PT3053576T (pt)	2018-10-08
SI3050564T1 (sl)	2020-02-28
CN103200941B (zh)	2015-12-16
IL225280A0 (en)	2013-06-27
WO2012037453A1 (en)	2012-03-22
ZA201302193B (en)	2013-11-27
US20130296394A1 (en)	2013-11-07
AR083019A1 (es)	2013-01-23
DK3053576T3 (en)	2018-08-20
EP2616068B1 (en)	2016-07-13
HK1185540A1 (en)	2014-02-21
KR102139905B1 (ko)	2020-07-31
DK3636263T3 (da)	2022-01-10
KR20140005154A (ko)	2014-01-14
ZA201302291B (en)	2013-11-27
HK1257416A1 (en)	2019-10-18
PL2616069T3 (pl)	2017-04-28
EP3050563A1 (en)	2016-08-03
US20150148394A1 (en)	2015-05-28
IL225278A (en)	2015-11-30
MY191369A (en)	2022-06-20
EP3050564B1 (en)	2019-09-04
TW201305117A (zh)	2013-02-01
CN103200941A (zh)	2013-07-10
DK3050564T3 (da)	2019-11-25
CA2811559A1 (en)	2012-03-22
AU2011301932C1 (en)	2016-09-01
KR102104760B1 (ko)	2020-04-27
CL2013000735A1 (es)	2013-11-29
US8492422B2 (en)	2013-07-23
PL3348264T3 (pl)	2020-08-24
ZA201302288B (en)	2013-11-27
US8653123B2 (en)	2014-02-18
EP3050564A1 (en)	2016-08-03
MX2013003009A (es)	2013-06-28
EP3636263A1 (en)	2020-04-15
US20120122945A1 (en)	2012-05-17
AR083020A1 (es)	2013-01-23
TWI591058B (zh)	2017-07-11
DK3338777T3 (da)	2020-04-20
SG188571A1 (en)	2013-04-30
UA112973C2 (uk)	2016-11-25
BR112013006320B1 (pt)	2022-08-30
EP3053576B1 (en)	2018-05-16
JP6073229B2 (ja)	2017-02-01
EP2616069A1 (en)	2013-07-24
AU2011301847B2 (en)	2016-02-11
EP2616068A1 (en)	2013-07-24
TW201305116A (zh)	2013-02-01
ES2781681T3 (es)	2020-09-04
SI3053576T1 (sl)	2018-11-30
KR20190022895A (ko)	2019-03-06
HUE048725T2 (hu)	2020-09-28
DK2616068T3 (en)	2016-08-29
KR102354097B1 (ko)	2022-01-20
RU2612351C2 (ru)	2017-03-07
CA3116249A1 (en)	2012-03-22
CA2812197C (en)	2024-01-02
ES2613509T3 (es)	2017-05-24
EP3338777A1 (en)	2018-06-27
AU2011301932A1 (en)	2013-05-02
EP3338777B1 (en)	2020-02-05
IL225282A0 (en)	2013-06-27
SG188573A1 (en)	2013-04-30
EP3078376A1 (en)	2016-10-12
HUE047476T2 (hu)	2020-04-28
CL2013000736A1 (es)	2013-07-12
JP2013537236A (ja)	2013-09-30
ES2737230T3 (es)	2020-01-10
US8853251B2 (en)	2014-10-07
RU2013116405A (ru)	2014-10-27
MX2013003002A (es)	2013-06-28
DK3050563T3 (en)	2018-08-13
KR20200044147A (ko)	2020-04-28
PT3348264T (pt)	2020-04-02
CA3077732A1 (en)	2012-03-22
RU2013116541A (ru)	2014-10-27
CY1122809T1 (el)	2021-05-05
MY161607A (en)	2017-04-28
ZA201302194B (en)	2013-11-27
KR101952457B1 (ko)	2019-02-26
EP3348264B1 (en)	2020-01-01
EP2616066A1 (en)	2013-07-24
PL3053576T3 (pl)	2018-11-30
KR101840500B1 (ko)	2018-03-20
BR112013006320A2 (pt)	2016-06-21
EP2616066B1 (en)	2016-07-13
JP2013537237A (ja)	2013-09-30
AU2011301856A1 (en)	2013-05-02
BR112013006352A2 (pt)	2016-06-28
CY1122958T1 (el)	2021-10-29
HK1185541A1 (zh)	2014-02-21
MY168763A (en)	2018-12-04
SI3050563T1 (sl)	2018-10-30
PT2616069T (pt)	2016-12-06
AU2011301901A1 (en)	2013-05-02
EP2616067B1 (en)	2016-05-18
CL2013000734A1 (es)	2013-11-08
MY173846A (en)	2020-02-24
KR20140003407A (ko)	2014-01-09
EP3698789A1 (en)	2020-08-26
KR20130114140A (ko)	2013-10-16
CN105412092A (zh)	2016-03-23
DK3348264T3 (da)	2020-03-23
EP3078376B1 (en)	2019-03-27
CN103200942A (zh)	2013-07-10
TR201909249T4 (tr)	2019-07-22
US8492557B2 (en)	2013-07-23
US20130289088A1 (en)	2013-10-31
JP2013541527A (ja)	2013-11-14
CY1121024T1 (el)	2019-12-11
ES2687420T3 (es)	2018-10-25
SG188572A1 (en)	2013-04-30
SG188570A1 (en)	2013-04-30
CA3122745A1 (en)	2012-03-22
US20120149746A1 (en)	2012-06-14
HUE049573T2 (hu)	2020-10-28
US20140057958A1 (en)	2014-02-27
JP6045495B2 (ja)	2016-12-14
US20120136036A1 (en)	2012-05-31
HK1185538A1 (zh)	2014-02-21
IL225281A0 (en)	2013-06-27
PT3338777T (pt)	2020-05-06
NZ608751A (en)	2015-04-24
EP3636263B1 (en)	2021-11-03
PT3050563T (pt)	2018-10-01
AR083017A1 (es)	2013-01-23
BR112013006362A2 (pt)	2016-06-28
KR20200091507A (ko)	2020-07-30
AU2011301856C1 (en)	2016-09-08
MX2013003008A (es)	2013-06-28
SI3338777T1 (sl)	2020-08-31

Publication	Publication Date	Title
CL2012003415A1 (es)	2013-08-09	Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
SMT201600216B (it)	2016-08-31	Ottaidropirrolo[3,4.c]pirroli disostituiti come modulatori del recettore di orexina
MX336741B (es)	2016-01-29	Composiciones farmaceuticas de moduladores de c-met.
CO6450665A2 (es)	2012-05-31	Anticuerpos anti-fgfr3 y métodos que los utilizan
EA201590292A1 (ru)	2015-10-30	Соединения, которые являются sip-модулирующими агентами и/или atx-модулирующими агентами
CL2012000921A1 (es)	2012-09-14	Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
EP2695080A4 (en)	2014-12-31	CONTINUOUS APPLICATION BETWEEN PLATFORMS
EP2749621A4 (en)	2015-05-06	RESIN COMPOSITION FOR ADHESIVES WITH PLATE-SHAPED INORGANIC COMPOUND AND ADHESIVE
FR2962442B1 (fr)	2016-02-26	Composition stable de 2,3,3,3-tetrafluoropropene
DK2753605T3 (da)	2019-06-17	Sammensætninger, fremgangsmåder, og systemer til syntesen og anvendelsen af billeddannelsesmidler
GT201300196A (es)	2014-06-06	Moduladores del receptor de glucagón
CO6321189A2 (es)	2011-09-20	Compuestos de tiazol y oxazol de bencen-sulfonamida
CL2011000976A1 (es)	2012-02-24	Compuestos derivados de isonicotinamida y carboxamida, antagonistas de los receptores de orexina; composicion farmaceutica que los comprende; y su uso para la prevencion de un trastorno del sueno.
MA54411A (fr)	2021-10-13	Compositions contenant de l'ibrutinib
BR112013003536A2 (pt)	2016-06-28	composição, e utilização de uma composição.
EA201590951A1 (ru)	2015-08-31	Дигидропиразольные модуляторы gpr40
EA201590954A1 (ru)	2015-08-31	Дигидропиразольные модуляторы gpr40
EA201101116A1 (ru)	2012-03-30	Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201590949A1 (ru)	2015-08-31	Дигидропиразольные модуляторы gpr40
EP2789245A4 (en)	2015-06-03	EMULSION COMPOSITION AND COMPOSITION / INGREDIENTS
CR20130147A (es)	2013-05-29	Combinaciones que contienen n-(2-arilamino)arilsulfonamida sustituida
UY34730A (es)	2013-10-31	Formulaciones farmacéuticas que comprenden antagonistas de ccr3
CL2014003429A1 (es)	2015-03-27	Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
DK2373652T3 (da)	2014-01-20	Substituerede piperidin-spiro-pyrrolidinon- og piperidinon-forbindelser anvendt som h3-modulatorer
CL2012003523A1 (es)	2014-02-14	Método para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable; composicion farmaceutica que contiene un portador de oxigeno altamente purificado y termoestable.